Trial Profile
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Procarbazine; Vincristine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BRAPP2
- 10 May 2021 Status changed from active, no longer recruiting to completed.
- 15 Aug 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.(Global end date: 2020-07-09)
- 12 Mar 2019 Status changed from recruiting to active, no longer recruiting.